A5035563902- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- vaccines and immunoinformatics approaches
- Viral Infections and Outbreaks Research
- Viral Infections and Vectors
- Animal Virus Infections Studies
- Immunotherapy and Immune Responses
- Respiratory viral infections research
- Hepatitis B Virus Studies
- Viral gastroenteritis research and epidemiology
- Energy and Environment Impacts
- Medical and Biological Ozone Research
- COVID-19 and Mental Health
- RNA Interference and Gene Delivery
- Antimicrobial Peptides and Activities
- Immune Response and Inflammation
- COVID-19 epidemiological studies
- Influenza Virus Research Studies
- COVID-19 and healthcare impacts
- T-cell and B-cell Immunology
- Hepatitis C virus research
- Renal Transplantation Outcomes and Treatments
Academy of Military Medical Sciences
2024
China Animal Health and Epidemiology Center
2024
National Vaccine and Serum Institute
2023
Beijing Fengtai Hospital
2023
Hengshui University
2020
The continuous emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants highlights the need to update coronavirus 2019 disease (COVID-19) vaccine components. Epitope-based designs targeting conserved and immunorecessive regions SARS-CoV-2 are critically needed. Here, we report an engineered epitope-focused immunogen design based on a novel horseshoe-shaped natural protein scaffold, named ribonuclease inhibitor 1 (RNH1), that can multiply display neutralizing...
Abstract The SARS-CoV-2 Omicron variant has become the dominant around world and exhibits immune escape to current COVID-19 vaccines some extent due its numerous spike mutations. Here, we evaluated responses booster vaccination with intramuscular adenovirus-vectored vaccine (Ad5-nCoV), aerosolized Ad5-nCoV, a recombinant protein subunit (ZF2001) or homologous inactivated (CoronaVac) in those who received two doses of 6 months prior. We found that Ad5-nCoV induced potent neutralizing activity...
T-cell immunity plays an important role in the control of SARS-CoV-2 and has a great cross-protective effect on variants. The Omicron BA.1 variant contains more than 30 mutations spike severely evades humoral immunity. To understand how affect cellular immunity, epitopes wild-type BALB/c (H-2d) C57BL/6 mice (H-2b) were mapped through IFNγ ELISpot intracellular cytokine staining assays. identified verified splenocytes from vaccinated with adenovirus type 5 vector encoding homologous spike,...
Rift Valley fever virus (RVFV) is listed as a priority pathogen by the World Health Organization (WHO) because it causes serious and fatal disease in humans, there are currently no effective countermeasures. Therefore, urgent to develop safe efficacious vaccine. Here, we developed six nucleotide-modified mRNA vaccines encoding different regions of Gn Gc proteins RVFV encapsulated lipid nanoparticles, compared their ability induce immune responses mice found that vaccine full-length had...
The SARS-CoV-2 Omicron variant has become the dominant and exhibits immune escape to current COVID-19 vaccines, further boosting strategies are required.We have conducted a non-randomized, open-label parallel-controlled phase 4 trial evaluate magnitude longevity of responses booster vaccination with intramuscular adenovirus vectored vaccine (Ad5-nCoV), aerosolized Ad5-nCoV, recombinant protein subunit (ZF2001) or homologous inactivated (CoronaVac) in those who received two doses vaccines.The...
The vaccine-induced innate immune response is essential for the generation of an antibody response. To date, how Ad5-vectored vaccines are influenced by preexisting anti-Ad5 antibodies during activation early remains unclear. Here, we investigated specific alterations in GP
Background: Few studies have examined the association between treatment given time and clinical outcomes, which is indeed of great importance to management coronavirus disease 2019 (COVID-19). We performed this study explore whether early brings favorable outcomes. Methods: In retrospective multicenter study, we included patients aged 18 87 years with confirmed COVID-19 on admission from 54 hospitals in nine provinces China 21 January 10 March, 2020. Final date follow-up was March 17, All...